ClinicalTrials.gg
RecruitingNCT07802301Updated Nov 5, 2026

taVNS in Infants Severe Dysphagia

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Oral Sensorimotor Training Protocol in Dysphagia, Swallowing Disorders and Feeding and Eating Disorders of Infancy, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

Updated Nov 5, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
Up to 6 Months
Sex
All
01

Study summary

This study evaluates the safety, feasibility, and preliminary effects of transcutaneous auricular vagus nerve stimulation (taVNS) paired with an oral sensorimotor training protocol in infants with severe dysphagia. Infants with significant sucking and swallowing impairment will receive twice-daily taVNS paired with oromotor training over a three-week period. Outcomes include swallowing mechanics, sucking proficiency, and functional feeding performance assessed before and after the intervention.

02

Conditions studied

  • Dysphagia
  • Swallowing Disorders
  • Feeding and Eating Disorders of Infancy

Keywords

  • Transcutaneous Auricular Vagus Nerve Stimulation
  • Oromotor Training
  • Dysphagia
  • Feeding Disorders
03

In context

Deglutition Disorders

871 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

This study's planned enrollment of 12 is below the median of 60 across 578 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 166 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants ≥37 weeks post-menstrual age
  • Diagnosed with dysphagia and significant sucking/swallowing impairment
  • Limited oral feeding ability
  • Admitted to NICU

Exclusion criteria

Exclusion Criteria:

  • Cardiomyopathy
  • Unstable bradycardia
  • Significant respiratory support requirement
  • Absence of gag reflex
  • Inability to manage secretions
  • Infants of poorly controlled diabetic mothers
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    taVNS Paired Oromotor Training

    Infants will receive transcutaneous auricular vagus nerve stimulation (taVNS) paired with an oral sensorimotor training protocol twice daily for 15 days over three weeks.

    Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) · Behavioral: Oral Sensorimotor Training Protocol

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation (taVNS)

    A non-invasive neuromodulation intervention delivered via electrodes placed on the ear tragus. Electrical stimulation is delivered at low intensity during feeding-related oromotor training sessions.

  • BehavioralOral Sensorimotor Training Protocol

    A structured oromotor stimulation protocol including stimulation of lips, tongue, cheeks, and palate, along with non-nutritive sucking and feeding practice as appropriate.

06

What researchers measure

Primary outcomes

  1. Change in swallowing impairment as measured by the BaByVFSImP

    Swallowing mechanics will be assessed using the Baby Videofluoroscopic Swallow Study Impairment Profile, a standardized scoring tool used to evaluate physiologic components of infant swallowing during videofluoroscopic swallow study. Scores will be compared from pre-treatment to post-treatment to determine change in swallowing impairment. Lower scores indicate less impairment.

    Time frame: Pre-treatment baseline and post-treatment, following completion of the 3-week intervention period

  2. Change in airway protection as measured by the Penetration-Aspiration Scale

    Airway protection during swallowing will be assessed using the Penetration-Aspiration Scale from videofluoroscopic swallow study recordings. Scores describe the depth of airway invasion and the infant's response to material entering the airway. Scores will be compared from pre-treatment to post-treatment. Lower scores indicate better airway protection.

    Time frame: Pre-treatment baseline and post-treatment, following completion of the 3-week intervention period

  3. Change in early feeding skills as measured by the Early Feeding Skills Assessment

    Feeding skills will be assessed using the Early Feeding Skills Assessment, a standardized clinical assessment used to evaluate infant feeding readiness, oral feeding skills, physiologic stability, and feeding tolerance. Scores will be compared from pre-treatment to post-treatment to evaluate change in functional feeding performance. Higher scores indicate more mature or more effective feeding skills.

    Time frame: Pre-treatment baseline and post-treatment, following completion of the 3-week intervention period

  4. Change in sucking pressures

    Sucking pressures will be measured. Values will be compared from pre-treatment to post-treatment to evaluate change in sucking mechanics.

    Time frame: Pre-treatment baseline and post-treatment, following completion of the 3-week intervention period

  5. Change in oral feeding volume

    Oral feeding volume will be measured as the amount of prescribed feeding volume taken orally. Oral intake volume will be compared from pre-treatment to post-treatment to determine change in functional oral feeding ability. Greater oral intake volume indicates improved feeding performance.

    Time frame: Pre-treatment baseline and post-treatment, following completion of the 3-week intervention period

Secondary outcomes

  1. Number of bradycardia events during intervention

    Safety will be assessed by recording the number of bradycardia events occurring during intervention sessions. Bradycardia will be defined as heart rate less than 80 beats per minute for 5 seconds or longer during a feed. Events will be recorded per feeding session.

    Time frame: During each intervention session throughout the 3-week intervention period

  2. Number of oxygen desaturation events during intervention

    Safety will be assessed by recording the number of oxygen desaturation events occurring during intervention sessions. Oxygen desaturation will be defined as oxygen saturation less than 80% for 5 seconds or longer during a feed. Events will be recorded per feeding session.

    Time frame: During each intervention session throughout the 3-week intervention period

  3. Number of coughing or choking episodes during intervention

    Safety will be assessed by recording the number of coughing or choking episodes occurring during intervention sessions. Events will be recorded per feeding session to monitor clinical signs of feeding intolerance or airway compromise.

    Time frame: During each intervention session throughout the 3-week intervention period

  4. Intervention completion rate

    Feasibility will be assessed by determining the number and percentage of enrolled infants who complete the full 3-week paired taVNS and oromotor training intervention. Completion will be defined as finishing the planned intervention period.

    Time frame: End of the 3-week intervention period

  5. Protocol adherence rate

    Feasibility will be assessed by recording the number and percentage of planned oromotor training sessions completed. Protocol adherence will be calculated as the number of completed sessions divided by the number of planned sessions.

    Time frame: Throughout the 3-week intervention period

  6. Oromotor treatment tolerance measured by adverse event rate per session

    Treatment tolerance will be assessed using an events-to-time ratio, calculated as the number of bradycardia and/or oxygen desaturation events occurring during each 30-minute oromotor training session. A lower event rate indicates better treatment tolerance.

    Time frame: During each 30-minute intervention session throughout the 3-week intervention period

07

Study locations

1 of 1 sites recruiting
  • Shawn Jenkins Children's Hospital
    Charleston, South Carolina 29401, United States
    Recruiting
08

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
1 site added — first site in United States
Show site
  • Shawn Jenkins Children's Hospital · Charleston, United States
Nov 5, 2026
Start date
Aug 30, 2026→Oct 19, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Shawn Jenkins Children's Hospital · Charleston, United States
    Start date Aug 30, 2026→Oct 19, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07802301
Collaborators
Zabara Foundation
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Oct 19, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Heather C McGhee, PhD
Contact
mcghee@musc.edu
7708834902
Doe Jenkins, MD
Contact
jenkd@musc.edu
8433642662

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion